Articles

By the The Reset Series editorial teamAugust 8, 2026Grounded in FDA prescribing information · STEP, SURMOUNT & SELECT trials · the 2025 ACLM/ASN/OMA/TOS nutrition advisory

GLP-1 side effects: what's common and what isn't

The common effects and why they happen, plus the short list of symptoms that belong with a prescriber rather than a search bar.

One mechanism explains most of it

If you remember one thing, make it this: these medications slow how quickly your stomach empties. Food lingers, so you feel full sooner and stay full longer — a large part of the therapeutic effect. And because food lingers, you may also feel nauseated, get reflux, burp unpleasantly, and become constipated.

Delayed gastric emptying is the reason it works and the reason it can make you feel unwell. It is the same lever.

That reframe does real work. It converts “something is going wrong with me” into “this is the mechanism doing its job, and here is what’s worth watching.” It also explains why effects are most noticeable when the signal changes — starting out, and after any adjustment — and why they commonly settle as your system adapts.

The common ones

The frequently reported list: nausea, vomiting, diarrhea, constipation, reflux and heartburn, burping (often with a sulfur taste), abdominal discomfort, headache, fatigue, and injection-site reactions.

Two things need saying about the word “common.”

First, common does not mean acceptable at any intensity. There is a large difference between mild evening queasiness and vomiting several times a week, and only one of those is something to ride out.

Second, severity and duration are clinical information. They are the exact data a prescriber uses to decide whether anything should change. Scoring a side effect 0–3 each day for three weeks produces a far more useful object than a memory of “it’s been bad.”

What published guidance suggests

In 2025, four professional societies issued a joint advisory on nutrition for people on GLP-1 therapy. Managing gastrointestinal effects was one of its eight priorities.

For nausea: a small breakfast, then small meals roughly every three to four hours rather than fewer large ones, with adequate fluids. Very high-fat, greasy, and very sugary foods sit badly in a slow stomach for most people. Ginger and peppermint appear in the advisory, as do acupressure bands. Eating slowly and stopping earlier than you think you need to helps more than people expect, because the fullness signal now arrives late.

For constipation: a gradual increase in fiber — both soluble and insoluble, with prunes and other dried fruit named specifically — foods with higher water content, genuinely adequate fluids, and movement. Gradual matters; a sudden fiber increase in a slow gut tends to produce bloating rather than relief.

Medication options exist for both, over-the-counter and prescription. Which to use depends on your other medications and conditions, so that is a question for a prescriber or pharmacist — pharmacists are underrated for exactly this.

The fatigue nobody warns you about

Fatigue is extremely common early and is the effect people most often suffer through silently. It is usually not one thing: you are eating substantially less, you may be under-hydrated because drinking feels uncomfortable in a slow stomach, your protein intake has likely dropped, nausea may be disrupting sleep, and blood sugar shifts add a layer if you have diabetes. Each produces tiredness, and they stack.

Treat fatigue as a signal to check the inputs rather than a fixed cost of treatment. See protein targets and meals for a small appetite.

The list that is not routine

Read this once properly, know the shapes, then stop scanning yourself for them. That is the trade: attention now, peace of mind afterwards.

Pancreatitis. Severe, persistent abdominal pain — often upper abdomen, often radiating through to the back, frequently with vomiting, and usually severe enough that you would not describe it as an upset stomach. Rare; a 2025 meta-analysis across 62 randomized trials found a relative risk of about 1.44, a modest increase on a small baseline. Risk factors include gallstones, high triglycerides, and rapid weight loss.

Gallbladder problems. Rapid weight loss of any kind is itself a well-established gallstone risk factor. In trial data, gallbladder-related disorders occurred in about 2.6% on semaglutide versus about 1.2% on placebo. The shape: severe pain in the upper right abdomen, often worse after fatty meals, sometimes with fever or yellowing of skin or eyes.

Sudden vision change. There is an association under investigation between semaglutide and NAION — non-arteritic anterior ischemic optic neuropathy — causing sudden, painless vision loss, typically in one eye. It has been added to European labeling for semaglutide. Rare, and any sudden vision change is an urgent evaluation regardless of cause.

Dehydration and kidney injury. The most common serious problem and the most preventable. Severe or persistent vomiting or diarrhea can dehydrate you enough to cause acute kidney injury.

Obstruction or severe gastroparesis. Persistent vomiting, inability to keep fluids down, or severe bloating with no bowel movement and no passing of gas.

Low blood sugar. Rare from these medications alone, but real when combined with insulin or a sulfonylurea. If you take either, that interaction is a required conversation.

What’s on the label

Three facts appear in the FDA prescribing information, and you should know you are on them rather than discovering them later from a stranger’s video.

There is a boxed warning — the FDA’s most prominent format — about thyroid C-cell tumors seen in rodent studies at clinically relevant exposures. Whether this applies to humans has not been determined. Relatedly, these medications are contraindicated with a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2. If that history exists in your family and nobody asked, raise it.

And they are not for use in pregnancy — animal data indicate potential fetal harm.

One practical item people are rarely told: because these medications delay gastric emptying, anyone giving you sedation needs to know you take one — it affects aspiration risk planning. Tell the surgeon, anesthesiologist, endoscopist, and dentist, at booking and again on the day. This applies to routine procedures, not just major surgery.

Call your prescriber if

• Severe or persistent abdominal pain, especially radiating to your back — urgent
• Vomiting you can’t stop, or inability to keep fluids down for 24 hours
• Signs of dehydration: dizziness on standing, very dark urine, no urination for many hours, confusion
• Any sudden change in vision, particularly in one eye — urgent
• Severe upper-right abdominal pain, fever, or yellowing of skin or eyes
• Severe bloating with no bowel movement and no gas passing
• Symptoms of low blood sugar if you also take insulin or a sulfonylurea
• Any side effect that is severe, getting worse rather than better, or stopping you eating and drinking normally

For how to raise these productively in a short appointment, see questions to ask your prescriber.

Not ready? Start with The First Week Survival Pages — free — one PDF, sent to your email, no card.

Common questions

Where this comes from

FDA prescribing information for the approved GLP-1 receptor agonists; the peer-reviewed trial literature (STEP, SURMOUNT, SELECT); and Nutritional priorities to support GLP-1 therapy for obesity, the 2025 joint advisory of the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. We use no influencer, telehealth-marketing, or supplement-industry sources.

Educational content from The Reset Series. Not medical advice, not a diagnosis, and no dosing guidance — dose decisions belong to the clinician who wrote your prescription. If you have symptoms that concern you, contact your prescriber. In an emergency, call 911. We are not affiliated with any pharmaceutical company; we sell no medications and provide no prescriptions.